A Phase II Clinical Trial of Radium-223 Activity in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) With Asymptomatic Progression While on Abiraterone Acetate or Enzalutamide Besides AR-V7 Mutational Status
Overview
- Phase
- Phase 2
- Intervention
- radium-223
- Conditions
- Prostate Cancer
- Sponsor
- MedSIR
- Enrollment
- 52
- Locations
- 2
- Primary Endpoint
- Assess the Efficacy of Radium-223 in Terms of Radiological rPFS
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
Radium-223 is indicated for the treatment of patients with mCRPC with symptomatic bone metastases and no known visceral metastatic disease. However, very few data have been reported in patients with mCRPC who are asymptomatic or mildly symptomatic. Recently, results from an International Expanded Access Program have also suggested a benefit of radium-223 in asymptomatic patients with mCRPC. In addition, the mechanism of action of radium-223 should not be correlated with the presence/absence of the AR-V7 mutation, although this issue has not yet been evaluated.
The aim of this study is to assess the efficacy of radium-223 in asymptomatic patients with mCRPC, and to establish the association between AR-V7 status and radium-223 activity.
Detailed Description
Primary objective: To assess the efficacy of radium-223 in asymptomatic patients with mCRPC who have progressed while on abiraterone acetate or enzalutamide treatment. Primary endpoint: To determine the efficacy of radium-223 in terms of radiological rPFS. Secondary objectives: * Safety profile. * To determine the association between AR-V7 status (positive vs. negative) and PFS. * To establish the relationship between CTCs number with radium-223 efficacy. Secondary endpoints: Safety AEs will be evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) of the US National Cancer Institute (NCI) version 4.0 \[20\]. Grade 3 or 4 AEs and serious adverse events (SAEs) will be assessed to determine the safety and tolerability of the various combinations of drugs. Efficacy * Radiographic progression-free survival (rPFS) depending on AR-V7 status. * Overall survival (OS). * Time to first symptomatic skeletal event (SSE). * Time to prostate specific antigen (PSA) progression according to the Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) study criteria. * Determination percentage of PSA progression. * Alkaline phosphatase level response (AF), normalization of alkaline phosphatase level, according to the ALSYMPCA study criteria. Molecular aspects * Assessment of AR-V7 mutation evolution during the study treatment. * Determination changes in CTCs number during the study treatment.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subject is an adult ≥ 18 years at the time of informed consent and has signed informed consent before any trial related activities and according to local guidelines.
- •Subject has histologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features.
- •Subject has bone metastases due to the prostate cancer and absence of visceral metastases.
- •Subject has a serum testosterone of ≤ 1.7 nmol/L (or ≤ 50 ng/dL) at screening.
- •Subject must have received a minimum of 24 weeks of treatment with abiraterone acetate or enzalutamide within its approved label indication and has discontinued use at least four weeks prior to start of study drug at day
- •Prior use of docetaxel is allowed in castration-naïve patients (maximum of six cycles).
- •Subject receives and will continue to receive ongoing androgen deprivation with luteinising hormone-releasing hormone (LHRH) analogue therapy throughout the course of the study or has had a bilateral orchiectomy.
- •Subject is asymptomatic from prostate cancer, defined as patients with the score on brief pain inventory (short form) (BPI-SF) Question #3 must zero and no use of opiate analgesics for prostate cancer-related pain currently or anytime within two weeks prior to screening.
- •Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 at screening.
- •Subject receiving bisphosphonate or other approved bone-targeting therapy must have been on stable doses for at least four weeks prior to start of study drug at day
Exclusion Criteria
- •Subject has received any anti-neoplastic therapy (including ketoconazole and chemotherapy) following abiraterone acetate or enzalutamide discontinuation and prior to start of study drug at day
- •Subject has known or suspected brain metastases or active leptomeningeal disease.
- •Subject has concurrent disease or any clinically significant abnormality following the investigator's review of the physical examination and safety laboratory tests at screening, which in the judgment of the investigator would interfere with the subject's participation in this study or evaluation of study results.
- •Subject has a history of another invasive cancer within three years prior to screening, with the exceptions of non-melanoma skin cancers or a non-infiltrating muscle bladder cancer that have a remote probability of recurrence in the opinion of the investigator in consultation with the medical monitor.
- •Subject had major surgery within one month prior to screening.
- •Subject has received investigational therapy within 28 days or 5 half lives, whichever is longer, prior to start of study drug at day
- •Subject has absolute neutrophil count \< 1,500/μL, platelet count \< 100,000/μL, and hemoglobin \< 6.25 mmol/L (or \< 10 g/dL) at screening (Note: Subjects must not have received any growth factors or blood transfusions within seven days of the hematologic laboratory values obtained at screening).
- •Subject has total bilirubin \> 1.5 times the upper limit of normal (ULN) at screening, except for subjects with documented Gilbert's syndrome.
- •Subject has creatinine \> 2.5 mg/dL at screening.
- •Subject has albumin ≤ 30 g/L (or ≤ 3.0 g/dL) at screening.
Arms & Interventions
open-label
Patient will be treated with radium-223 at a dose of 55 kilobecquerel (kBq) (after 2015 National Institute of Standards and Technology's (NIST) implementation) per kilogram body weight, given at four-week intervals for six intravenous injections.
Intervention: radium-223
Outcomes
Primary Outcomes
Assess the Efficacy of Radium-223 in Terms of Radiological rPFS
Time Frame: From date of first drug administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months
The primary efficacy endpoint is the median PFS (evaluated using RECIST v1.1) achieved with radium-223 treatment
Secondary Outcomes
- AEs and Serious Adverse Events (SAEs)(Starting from the first procedure required by the study up to three months after study discontinuation.)
- Radiographic Progression-free Survival (rPFS) Depending on AR-V7 Status.(From date of inclusion until Radiographic progression, assessed up to 20 months)
- Overall Survival (OS).(From date of inclusion until death from any cause or the last date the patient was known to be alive, assessed up to 20 months.)
- Time to First Symptomatic Skeletal Event (SSE).(From date of first drug administration until SSE, assessed up to 20 months)
- Time to PSA Progression According to the ALSYMPCA Study Criteria.(From date of first study drug administration to when PSA progression is observed, assessed up to 20 months)
- PSA Progression(From date of first study drug administration to when PSA progression is observed, assessed up to 20 months)
- Alkaline Phosphatase Level Response (AF), Normalization of Alkaline Phosphatase Level(From date of first study drug administration until End of Treatment, assessed up to 6 months)
- Assessment of AR-V7 Mutation Evolution(From date of first study drug administration until End of Treatment, assessed up to 6 months)
- Number of Participants With Change in CTCs Number(From date of first study drug administration until End of Treatment, assessed up to 6 months)